Related Links:
For additional information about ROX Medical, please refer to the following links.
The WALK Trial is registered at clinicaltrials.gov
The WALK Trial is registered at clinicaltrials.gov
ROX Medical is an early phase medical device company that is pioneering an innovative treatment for Chronic Obstructive Pulmonary Disease (COPD). Our therapy is intended to improve the delivery of oxygen to tissue to treat hypoxemia in COPD patients via the creation of a therapeutic fistula.
Our device creates a passage between an artery and a vein in the pelvic region which redirects oxygen rich blood back to the lungs of severe COPD patients
ROX’s arteriovenous fistula was originally discovered in 2004 by researchers at Stanford University. Since then, ROX Medical has conducted clinical studies in Europe and Mexico that show encouraging results for COPD management. Due to the success of these early clinical trials, several leaders in Pulmonology and Physiology now serve as medical advisors for ROX Medical.
The Anastomotic Coupling Procedure is an experimental COPD treatment option that is not yet commercially available in the United States. However, clinical trials of the device are being conducted at study sites throughout the country.
Our device creates a passage between an artery and a vein in the pelvic region which redirects oxygen rich blood back to the lungs of severe COPD patients
ROX’s arteriovenous fistula was originally discovered in 2004 by researchers at Stanford University. Since then, ROX Medical has conducted clinical studies in Europe and Mexico that show encouraging results for COPD management. Due to the success of these early clinical trials, several leaders in Pulmonology and Physiology now serve as medical advisors for ROX Medical.
The Anastomotic Coupling Procedure is an experimental COPD treatment option that is not yet commercially available in the United States. However, clinical trials of the device are being conducted at study sites throughout the country.